Abstract 11617: Cardiovascular Outcomes in Patients with Fatty Change of Liver Treated with Combined GLP-1 RA and SGLT2 Inhibitor Therapy versus GLP-1 RA Alone: A Propensity Score Matched TriNetX Analysis
Background: Fatty change of the liver is strongly associated with cardiovascular risk due to insulin resistance, dyslipidemia, and systemic inflammation. GLP-1 receptor agonists (GLP-1 RAs) and SGLT2 inhibitors (SGLT2is) each provide independent cardiovascular benefits. This study assesses whether combination therap...